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Abstract
C-reactive protein (CRP) is one of the most important biomarkers for arteriosclerosis and cardiovascular disease. Recent
studies have shown that CRP affects cell cycle and inflammatory process in cardiac myocytes. Survivin is also involved in
cardiac myocytes replication and apoptosis. Reduction of survivin expression is associated with less favorable cardiac
remodeling in animal models. However, the effect of CRP on survivin expression and its cellular mechanism has not yet been
studied. We demonstrated that treatment of CRP resulted in a significant decrease of survivin protein expression in a
concentration-dependent manner in cardiac myocytes. The upstream signaling proteins of survivin, such as Akt, mTOR and
p70S6K, were also downregulated by CRP treatment. In addition, CRP increased the protein and mRNA levels of PTEN. The
siRNA transfection or specific inhibitor treatment for PTEN restored the CRP-induced downregulation of Akt/mTOR/p70S6K
pathway and survivin protein expression. Moreover, pretreatment with a specific p53 inhibitor decreased the CRP-induced
PTEN expression. ERK-specific inhibitor also blocked the p53 phosphorylation and PTEN expression induced by CRP. Our
study provides a novel insight into CRP-induced downregulation of survivin protein expression in cardiac myocytes through
mechanisms that involved in downregulation of Akt/mTOR/p70S6K pathway by expression of PTEN.
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Introduction
C-reactive protein (CRP), which is an acute-phase protein, has
been described as a non-specific biomarker of inflammation and
risk factor for cardiovascular disease (CVD) [1]. CRP plays a
crucial role in the expression of adhesion molecules of endothelial
cells, the progression of atherosclerotic lesion, survival of
endothelial progenitor cell, activation of monocytes and expression
of tissue factor, the key initiator for thrombosis [2–5]. Recently,
Nagai et al. documented that CRP enhanced pressure overload-
induced cardiac remodeling through inflammatory response [6].
Our previous study showed that CRP induces p53-mediated cell
cycle arrest in H9c2 cardiac myocytes [7].
Survivin is a unique member of the inhibitor of apoptosis gene
family and its expression is an important factor in regulating
proper cell division and apoptosis [8–10]. It is also known that the
cellular stress response to an anti-apoptotic and mitotic checkpoint
is maintained by survivin [11]. It has been demonstrated that
phosphotidyliositol-3-kinase (PI3K), Akt and p70S6K1 pathway is
essential for regulating survivin expression in human ovarian cells
and prostatic cancer cells [12,13]. And, survivin plays a role in the
insulin-induced anti-apoptotic effect in the ischemic-reperfused
heart through PI3K/Akt/mammalian target of rapamycin
(mTOR) signaling pathway [14]. It was also reported that
ventricular function was decreased in a survivin knock-out mouse
model [15]. Furthermore, reduction of survivin expression is
associated with induced apoptosis and pressure-overload cardiac
remodeling process in spontaneously hypertensive rat [16].
Recently, we demonstrated that anti-apoptotic effect of survivin
in doxorubicin-induced cell death in H9c2 cardiac myocytes [17].
Therefore, we can speculate the possible interaction between CRP
and survivin in the process of cell survival pathway. To our
knowledge, the effect of CRP on survivin expression in cardiac
myocytes has not been determined. In the present study, we
investigated whether and how CRP would regulate survivin
expression in cardiac myocytes.
Methods and Materials
Reagents and antibodies
Human CRP protein was purchased from Millipore. To remove
sodium azide from the commercial CRP preparation, CRP was
repeatedly filtered with Tris buffer (10 mM Tris, 100 mM NaCl
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and 2 mM Ca2+) until remaining 0.0001% sodium azide using
Ultrafilter Vivaspin 500 (Sartorius). Anti-survivin, anti-phospho-
p53 (Ser15), anti-p53, anti-phospho-Akt (Ser473), anti-Akt, anti-
phospho-mTOR (Ser2481) and anti-mTOR antibodies were
obtained from Cell Signaling. Anti-PTEN, anti-phospho-p70S6K
(Thr421/Ser424), anti-p70s6k, anti-phospho-ERK1/2 (Tyr204),
anti-ERK1/2 and anti-GAPDH antibodies were purchased from
Santa Cruz Biotechnology. BpV (PTEN inhibitor), U0126 (ERK
inhibitor), SP600125 (JNK inhibitor), CGK733 (ATM/ATR
inhibitor) and NU7026 (DNA-PK inhibitor) were purchased from
Calbiochem. PFT-a (p53 inhibitor) was obtained from Sigma-
Aldrich.
Cell culture
The rat heart-derived myoblast cell line, H9c2 cardiac
myocytes, was obtained from the American Type Culture
Collection. H9c2 cardiac myocytes were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplement with 10% fetal
bovine serum (FBS), 100 U/ml of penicillin and 100 mg/ml of
streptomycin (Gibco) at 37uC in a humidified atmosphere with 5%
CO2. All experiments were performed using cells between 15 to 25
passage numbers. H9c2 cardiac myocytes were incubated for
24 hours in 100 mm culture plate and changed to 0.5% FBS for
24 hours starvation. After starvation, cells were pretreated with 0
, 50 mg/ml CRP in 0.5% FBS for 24 hours.
Neonatal rat cardiac myocytes were also isolated from the
Sprague-Dawley rats on postnatal day 1 to 2. Cells were preplated
(2 hours) to enrich for cardiac myocytes, plated at a density 1500
cell/mm2, and cultured for 48 hours in Minimum Essential
Medium (MEM)-a containing 10% FBS, 100 U/ml of penicillin,
100 mg/ml of streptomycin (Gibco) and 100 mmol/L boromo-
deoxyuridine (Sigma). At 48 hours after plating, the culture media
was replaced with 0.5% FBS MEM-a. As assessed by immuno-
fluorescence with an antibody against a-sarcomeric actin and a-
smooth muscle actin, .95% of the isolated cells were cardiac
myocytes (data not shown).
Immunoblot analysis
Cells were solubilized in a cell lysis buffer (Cell Signaling) and
centrifuged at 14,000 rpm for 1 hour at 4uC. The protein samples
were separated by a SDS-polyacrylamide gel and then electro-
transferred to polyvinylidene difluoride membranes. The mem-
branes were washed with Tris-buffered saline-tween 20 (TBS-T)
and blocked by incubation with 10% nonfat dry milk in TBS-T for
1 hour at room temperature. The membranes were incubated
with indicated primary antibodies for overnight. After washing,
they were incubated with horseradish peroxidase-conjugated
secondary antibody for 1 hour and subjected to enhanced
chemiluminescence detection. The loading control was performed
on the same membrane after stripping.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total ribonucleic acid (RNA) isolated from cardiac myocytes
using QIAzol-Regent (Qiagen) was reverse transcribed using
Omniscript Reverse Transcriptase (Qiagen). The cDNAs was
amplified using Taq deoxyribonucleic acid (DNA) polymerase
(Takara, Japan). The following primer sequences were used:
survivin primers 5’-ATGGGTGCTACGGCGCTGCCC-3’ and
5’-TCAGCGTAAGGCAGCCAGCTG-3’, PTEN primers 5’-
AGACCATAACCCACCACAGC-3’ and 5’-TTACAC-
CAGTCCGTCCTTTCC-3’, GAPDH primers 5’-AATG-
CATCCTGCACCACCAACTGC-3’ and 5’-GGAGGCCATG-
TAGGCCATGAGGTC-3’. Polymerase chain reaction (PCR)
products were separated by electrophoresis in a 1% agarose gel
containing Gel-red (Biotium).
siRNA transfection
Scrambled control siRNA were purchased from Santa Cruz
Biotechnology. PTEN siRNA targeting sequences, 5’-CAAGAU-
CUUCACAAAAGGGUU-3’, was obtained from Genolution
Pharmaceuticals. Cells were transfected with 20 nM of siRNA
using Lipofectamine RNA iMAX (Invitrogen) according to the
manufacturer’s protocol.
Immunofluorescence microscopy
Cells incubated on Lab-Tek chamber slides (Nalgene Nunc).
The cells were fixed with 3% paraformaldehyde for 10 min at
room temperature and washed with PBS. Cells were permeabi-
lized in 0.5% Triton X-100 buffer (0.5% Triton X-100, 20 mM
Hepes-KOH, pH 7.9, 50 mM NaCl, 3 mM MgCl2, 300 mM
sucrose) in PBS for 10 min and washed with PBS. They were
blocked with PBS containing 0.3% goat serum and 5% bovine
serum albumin for 1 hour at room temperature and then
incubated for 1 hour with a-sarcomeric actin antibody (dilution
1:200; Thermo) and a-smooth muscle actin antibody (dilution
1:200; Abcam). Cells were washed with PBS and incubated with
Alexa fluor 488 and rhodamine Red-X (dilution 1:500; Invitrogen)
as secondary antibody for 1 hour in dark room. After washing, the
cells were mounted with ProLongantifade reagent containing
DAPI. The immunoreactive signals were visualized by confocal
laser scanning microscope LSM700 (Carl Zeiss, Germany).
Statistical analysis
All measured data was displayed as average 6 S.E. The
differences between the groups were compared by the unpaired
one-way analysis of variance and Student’s t-test, followed by post
hoc analysis Bonferroni test. Differences were considered significant
at P,0.05.
Results
CRP inhibits survivin expression in H9c2 cardiac
myocytes
We first investigated the effect of CRP on survivin expression in
H9c2 cardiac myocytes. Cells were pretreated with various
concentrations of CRP with 0.5% FBS for 24 hours and incubated
with 10% FBS for 24 hours. As shown in Fig. 1A, serum-deprived
H9c2 cardiac myocytes exhibited low expression of baseline
endogenous survivin. After 24 hours incubation with 10% FBS,
survivin expression level was significantly increased. However,
survivin protein levels were decreased by CRP in a concentration-
dependent manner (Fig. 1A). Fig. 1B shows the time-dependent
decrease of survivin protein level, when pretreated with 50 mg/ml
of CRP for variable time. We further studied changes in mRNA
level of survivin by CRP pretreatment. RT-PCR showed that
there were no changes in survivin mRNA levels (Fig. 1C). These
data suggest that CRP decreases survivin protein level without
change of mRNA level in H9c2 cardiac myocytes.
CRP downregulates Akt/mTOR/p70S6K pathway
The regulatory mechanism of survivin expression level through
Akt, mTOR and p70S6K signaling has been reported [12,13]. So
we first examined phosphorylation pattern of Akt, mTOR and
p70S6K in 10% FBS-treated H9c2 cardiac myocytes. As shown in
Fig. 2A, the time-dependent maximum increase in phosphoryla-
tion of Akt, mTOR and p70S6K were observed, when incubated
C-Reactive Protein Inhibits Survivin Expression
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with 10% FBS for 1 hour. As shown in Fig. 2B, increased
phosphorylation levels of Akt, mTOR, and p70S6K after 10%
FBS incubation were significantly reduced, when pretreated
50 mg/ml of CRP for 24 hours. These results suggest that CRP
regulates survivin protein level through Akt/mTOR/p70s6k
pathway in H9c2 cardiac myocytes.
PTEN is an upstream target of Akt, mTOR and p70s6k for
regulating survivin expression by CRP
Since phosphatase and tensin homologue deleted from chro-
mosome ten (PTEN) regulates PI3K/Akt signal pathway [18], we
first examined PTEN level in CRP-treated H9c2 cardiac
myocytes. Interestingly, CRP significantly increased protein and
mRNA level of PTEN (Fig. 3A). To investigate the role of PTEN
in CRP-pretreated H9c2 cardiac myocytes, siRNA for PTEN gene
was used to knock-down the expression. Transfection with PTEN
siRNA effectively decreased the protein and mRNA level of PTEN
in H9c2 cardiac myocytes (Fig. 3B). Downregulation of PTEN
with siRNA significantly recovered the decreased phosphorylation
of Akt, mTOR, p70S6K, and survivin protein level in CRP-
pretreated H9c2 cardiac myocytes (Fig. 3B and C). Moreover,
pretreatment with BpV, a specific PTEN inhibitor also recovered
the decreased phosphorylation of Akt, mTOR p70S6K, and
survivin protein level (Fig. 3D and E). These results indicate that
PTEN is an upstream target of Akt/mTOR/p70S6K pathway for
regulating survivin protein level.
CRP increases PTEN expression through activation of p53
by ERK1/2
It has been reported that regulation of PTEN transcription by
activation of p53 [19]. Recently, we demonstrated that CRP-
induced p53 activation is mediated by ERK1/2 which activated
through the binding of CRP to FccRIIIa in H9c2 cardiac
myocytes [7]. Therefore, we investigated the effect of several
kinase inhibitors on protein and mRNA level of PTEN upregula-
tion induced by CRP treatment. As shown in Fig. 4A and B, when
pretreated with p53 inhibitor, PFT-a, the protein and mRNA
levels of PTEN were significantly suppressed in CRP-pretreated
H9c2 cardiac myocytes. In addition, CRP-induced p53 phosphor-
ylation and PTEN expression were significantly suppressed by
treatment with ERK inhibitor, U0126 (Fig. 4C and D). There
were no clear changes in PTEN protein level by other inhibitors
including ATM/ATR inhibitor, DNA-PK inhibitor, and JNK
inhibitor (data not shown).
CRP inhibits phosphorylation of Akt, mTOR, p70S6K and
survivin protein expression through PTEN expression in
neonatal rat cardiac myocytes
We also demonstrated the effect of CRP on survivin expression
in neonatal rat cardiac myocytes. Moreover, pretreatment with
Figure 1. Effect of CRP on protein and mRNA level of survivin
in H9c2 cardiac myocytes. (A) H9c2 cardiac myocytes were
pretreated for 24 hours with various concentrations of CRP in 0.5%
FBS and then treated 10% FBS for 24 hours. Whole cell lysates were
Immunoblot analysis with anti-survivin antibody. *P,0.05 compared to
control (10% FBS treatment without CRP). (B) H9c2 cells were
pretreated with 50 mg/ml of CRP for indicated times and then treated
10% FBS for 24 hours. Protein levels of survivin were analyzed by
immunoblot assay. *P,0.05 compared to control. (C) H9c2 cells were
pretreated for 24 hours with CRP in 0.5% FBS and then treated 10% FBS
for 24 hours. Total RNA was purified and subjected to RT-PCR. All
experiments were performed independently at least three times. Data
are mean 6 S.E.
doi:10.1371/journal.pone.0098113.g001
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BpV, a specific PTEN inhibitor recovered the decreased
phosphorylation of Akt, mTOR p70S6K, and survivin protein
level (Fig. 5A and B). In the present study, we have showed that
PTEN is an upstream target of Akt/mTOR/p70S6K pathway for
regulating survivin protein level in neonatal rat cardiac myocytes.
We examined whether PTEN expression was affected by p53
activation in neonatal rat cardiac myocytes. When pretreated with
p53 inhibitor, PFT-a, the protein and mRNA levels of PTEN were
significantly suppressed in CRP-pretreated neonatal rat cardiac
myocytes. In addition, CRP-induced p53 phosphorylation and
PTEN expression were significantly suppressed by treatment with
ERK inhibitor, U0126 (Fig. 5C and D).
Discussion
CRP has been considered as an independent predictor of the
occurrence and progression of CVD by participating in a variety
of inflammatory processes. Furthermore, several reports from
several cell types suggest that CRP is a key role in cell
differentiation and cell cycle [1,7,9,20]. Survivin, although its
mechanism is not clearly understood, is also considered to be a key
factor in regulating cell survival and suppression of apoptosis [10].
In our previous study, CRP has no significant apoptotic effect for
24 hours on H9c2 cardiac myocytes [7]. Not only the survivin is
selectively expressed at the G2/M phase of the cell cycle in a cell
cycle-dependent manner, but also non-cell cycle dependent
mechanisms such as signal transducer and activator of transcrip-
tion 3 or PI3K activity affect survivin expression [8,13,21]. PI3K/
Akt signaling pathway has been implicated to play an important
role in the upregulation of survivin in certain cells [12,13].
However, there is no information about whether CRP would
modulate survivin expression in cardiac myocytes, or which
underlying mechanisms are involved. Our study is the first to
demonstrate that CRP inhibits survivin expression by PTEN/Akt
pathway in cardiac myocytes.
In the present study, we demonstrated that CRP inhibited
survivin protein level in a time- and concentration dependent
manner, but not survivin mRNA level in cardiac myocytes.
Stimulation of cardiac myocytes with CRP for 24 hours induced
marked expression of PTEN. Furthermore, knock-down of PTEN
using siRNA, or treatment of PTEN inhibitor, restored the
decreased survivin protein level induced by CRP. These survivin
protein expression levels were correlated with Akt/mTOR/
p70S6K activation, suggesting that Akt may be a downstream
target of PTEN. Both the ERK1/2 inhibitor and the p53 inhibitor
inhibited PTEN expression by CRP. These results may help to
understand how CRP affects survivin expression in cardiac
myocytes.
The PTEN has been known as a regulator of multiple signal
pathways that adjust cell cycle progression, cell proliferation and
apoptosis [22,23]. Also, PTEN is a negative regulator of PI3K/
Akt-dependent signaling by dephosphorylating phosphatidylinosi-
tol 3,4,5-triphosphate (PIP3) [18,24,25]. In the present study, we
found that long-term CRP exposure increased endogenous PTEN
protein and mRNA level, accompanied by reduced phosphoryla-
tion of Akt, mTOR and p70s6k, and reduced survivin protein level
in cardiac myocytes. This finding corresponds to the result that
chronic exposure to CRP induces PTEN upregulation in
endothelial cells [26]. In addition, the decreased protein level of
survivin by CRP was considerably reversed by knock-down of
PTEN with siRNA or treatment of PTEN inhibitor. These results
are in close agreement that PTEN antagonizes the action of PI3K
and reduces phosphorylation of downstream signal, Akt, thus
leading to the down-regulation of Akt survival signaling pathway
[27].
The p53 protein has low levels under normal condition in cells,
which exists in a largely inactive state. Activation of p53 in
response to various stimuli such as toxin, hypoxia and serum
deprivation is associated with an increase in its protein level and
phosphorylation activity. In our previous study [7], p53 phos-
phorylation on Ser15 increased following exposure to CRP in
Figure 2. Effect of CRP on the Akt/mTOR/p70S6K pathway in
H9c2 cardiac myocytes. (A) After 24 hours of serum starvation, H9c2
cells were treated with 10% FBS for indicated time. Cells were harvested
and analyzed for Akt/mTOR/p70S6K signaling pathway by immunoblot
assay. (B) H9c2 cells were pretreated for 24 hours with 50 mg/ml of CRP
in 0.5% FBS and then treated 10% FBS for 1 hour. The protein levels
were analyzed by immunoblot assay.
doi:10.1371/journal.pone.0098113.g002
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Figure 3. Role of PTEN in CRP-induced downregulation of Akt/mTOR/p70S6K pathway. (A) H9c2 cardiac myocytes were treated with
indicated concentration of CRP in 0.5% FBS for 24 hours. Expression levels of PTEN were determined by immunoblot analysis and RT-PCR,
respectively. (B) H9c2 cells transfected with 20 nM of PTEN siRNA were incubated 50 mg/ml of CRP in 0.5% FBS for 24 hours and then treated 10% FBS
for 1 hour. Cells were harvested and analyzed for PTEN, Akt, mTOR and p70S6K signaling pathway by immunoblot assay. (C) PTEN siRNA-transfected
cells were incubated 50 mg/ml of CRP in 0.5% FBS for 24 hours and then treated 10% FBS for 24 hours. Protein levels of PTEN or survivin were
analyzed by immunoblot assay. (D) H9c2 cells pretreated with PTEN inhibitor (BpV, 5 mM) for 1 hour were incubated with 50 mg/ml of CRP in 0.5% FBS
for 24 hours and then treated 10% FBS for 1 hour. Cells were harvested and analyzed for PTEN, Akt, mTOR and p70S6K signaling pathway by
immunoblot assay. (E) PTEN inhibitor-pretreated cells were incubated 50 mg/ml of CRP in 0.5% FBS for 24 hours and then treated 10% FBS for
24 hours. Protein levels of PTEN or survivin were analyzed by immunoblot assay.
doi:10.1371/journal.pone.0098113.g003
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H9c2 cardiac myocytes. We confirmed this finding in the present
study, and observed that pretreatment with a specific p53 inhibitor
inhibited CRP-induced PTEN expression. The PTEN promoter
contains a p53-binding element and PTEN transcription is
regulated by activation of p53. And a p53-independent element
controlling constitutive expression of PTEN was also identified
[19]. ERK1/2 has been shown to act as the upstream kinase for
phosphorylation of p53 at Ser15 in response to doxorubicin or
CRP in cardiac myocytes or macrophage cells [7,28-30]. In our
study, we observed that CRP induces PTEN expression through
activation of p53 by ERK1/2 in cardiac myocytes. Pretreatment
with an ERK inhibitor resulted in decreased phosphorylation at
Ser15 of p53 with decreasing PTEN protein and mRNA level.
Therefore, CRP-induced PTEN expression may be regulated by
p53 phosphorylation and transactivation through upstream
ERK1/2 activation. Our findings support the potential role of
CRP as a modulator for survivin expression, and the mechanism
by which CRP induces downregulation of Akt/mTOR/p70S6K
pathway through expression of PTEN in cardiac myocytes.
Figure 4. CRP-induced PTEN expression via ERK1/2 and p53 activation. H9c2 cardiac myocytes were pretreated with p53 inhibitor (PFT-a,
5 mM) for 1 hour and then treated with 50 mg/ml of CRP in 0.5% FBS for 24 hours. (A) Expression levels of phspho-p53, p53 and PTEN were analyzed
by immunoblot assay. (B) Total RNA was purified from cells and subjected to RT-PCR using primers specific for PTEN. H9c2 cells were pretreated with
ERK inhibitor (U0126, 5 mM) for 1 hour and then treated with 50 mg/ml of CRP 0.5% FBS for 24 hours. (C) Expression levels of PTEN were analyzed by
immunoblot assay. (D) The level of PTEN was determined by RT-PCR. The results present the means of three independent experiments. Data are mean
6 S.E. *P,0.05.
doi:10.1371/journal.pone.0098113.g004
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Figure 5. CRP downregulates Akt/mTOR/p70S6K pathway and survivin protein expression through PTEN expression in neonatal rat
cardiac myocytes. (A) After 24 hours of serum starvation, neonatal rat cardiac myocytes pretreated with PTEN inhibitor (BpV, 5 mM) for 1 hour were
incubated with 50 mg/ml of CRP in 0.5% FBS for 24 hours and then treated 10% FBS for 1 hour. Cells were harvested and analyzed for PTEN, Akt,
mTOR and p70S6K signaling pathway by immunoblot assay. (B) PTEN inhibitor-pretreated cells were incubated 50 mg/ml of CRP in 0.5% FBS for
24 hours and then treated 10% FBS for 24 hours. Protein levels of PTEN or survivin were analyzed by immunoblot assay. Neonatal rat cardiac
myocytes were pretreated with p53 inhibitor (PFT-a, 5 mM) or ERK inhibitor (U0126, 5 mM) for 1 hour then treated with 50 mg/ml of CRP 0.5% FBS for
24 hours. (C) The protein levels were analyzed by immunoblot assay. (D) Total RNA was purified from cells and subjected to RT-PCR using primers
specific for PTEN. The results present the means of three independent experiments. Data are mean 6 S.E. *P,0.05.
doi:10.1371/journal.pone.0098113.g005
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